Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Adjunctive cilostazol versus high maintenance dose of clopidogrel in patients with hyporesponsiveness to chronic clopidogrel therapy.

Lee GY, Hahn JY, Lee SY, Kim HJ, Kim JH, Lee SY, Song YB, Choi SH, Choi JH, Gwon HC.

Yonsei Med J. 2013 Jan 1;54(1):34-40. doi: 10.3349/ymj.2013.54.1.34.

PMID:
23225796
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.

Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, Kwak CH, Park SW.

Circ Cardiovasc Interv. 2010 Feb 1;3(1):17-26. doi: 10.1161/CIRCINTERVENTIONS.109.880179. Epub 2010 Jan 26.

PMID:
20118150
[PubMed - indexed for MEDLINE]
Free Article
4.

Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.

Ha SJ, Kim SJ, Hwang SJ, Woo JS, Kim W, Kim WS, Kim KS, Kim MK.

Coron Artery Dis. 2013 Dec;24(8):690-7. doi: 10.1097/MCA.0000000000000026.

PMID:
24152567
[PubMed - indexed for MEDLINE]
5.

Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.

Capranzano P, Ferreiro JL, Ueno M, Capodanno D, Dharmashankar K, Darlington A, Desai B, Tello-Montoliu A, Rollini F, Angiolillo DJ.

Catheter Cardiovasc Interv. 2013 Jan 1;81(1):42-9. doi: 10.1002/ccd.24416. Epub 2012 Apr 17.

PMID:
22431415
[PubMed - indexed for MEDLINE]
6.

Dual antiplatelet therapy clopidogrel with low-dose cilostazol intensifies platelet inhibition in patients with ischemic stroke.

Maruyama H, Fukuoka T, Deguchi I, Ohe Y, Nagoya H, Kato Y, Horiuchi Y, Hayashi T, Tanahashi N.

Intern Med. 2013;52(10):1043-7. Epub 2013 May 15.

PMID:
23676588
[PubMed - indexed for MEDLINE]
Free Article
7.

Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.

Yang TH, Kim DI, Kim DK, Jang JS, Kim U, Seol SH, Kim DK, Hong GR, Park JS, Shin DG, Kim YJ, Cho YK, Nam CW, Hur SH, Kim KB, Kim DS.

Korean J Intern Med. 2011 Jun;26(2):145-52. doi: 10.3904/kjim.2011.26.2.145. Epub 2011 Jun 1.

PMID:
21716590
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.

Hwang SJ, Jeong YH, Kim IS, Park KS, Kang MK, Koh JS, Park JR, Park Y, Koh EH, Kwak CH, Hwang JY, Kim S.

Circ Cardiovasc Interv. 2010 Oct;3(5):450-9. doi: 10.1161/CIRCINTERVENTIONS.110.949859. Epub 2010 Sep 7.

PMID:
20823393
[PubMed - indexed for MEDLINE]
Free Article
9.

Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.

Kim IS, Jeong YH, Park Y, Park KS, Yun SE, Park JR, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S.

JACC Cardiovasc Interv. 2011 Apr;4(4):381-91. doi: 10.1016/j.jcin.2010.12.010.

PMID:
21511217
[PubMed - indexed for MEDLINE]
Free Article
10.

Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.

Yang TH, Jin HY, Choi KN, Do U, Kim HJ, Chung SR, Seo JS, Jang JS, Kim DK, Kim DS.

Int J Cardiol. 2013 Sep 20;168(1):207-11. doi: 10.1016/j.ijcard.2012.09.093. Epub 2012 Oct 26.

PMID:
23106905
[PubMed - indexed for MEDLINE]
11.

Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.

Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS.

J Am Coll Cardiol. 2011 Jan 18;57(3):280-9. doi: 10.1016/j.jacc.2010.08.631.

PMID:
21232664
[PubMed - indexed for MEDLINE]
Free Article
12.

Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.

Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V.

Thromb Res. 2007;119(3):277-84. Epub 2006 Mar 24.

PMID:
16563469
[PubMed - indexed for MEDLINE]
13.

Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy.

Angiolillo DJ, Capranzano P, Ferreiro JL, Ueno M, Capodanno D, Dharmashankar K, Darlington A, Sumner S, Desai B, Charlton RK, Box LC, Zenni M, Guzman LA, Bass TA.

Thromb Haemost. 2011 Aug;106(2):253-62. doi: 10.1160/TH11-01-0041. Epub 2011 May 26.

PMID:
21614414
[PubMed - indexed for MEDLINE]
14.

Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.

Sharma RK, Erickson SW, Sharma R, Voelker DJ, Reddy HK, Dod H, Marsh JD.

Vasc Health Risk Manag. 2013;9:187-93. doi: 10.2147/VHRM.S43909. Epub 2013 May 1.

PMID:
23662064
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.

Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ.

Thromb Haemost. 2008 Feb;99(2):409-15. doi: 10.1160/TH07-09-0575.

PMID:
18278193
[PubMed - indexed for MEDLINE]
16.

Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.

Kim IS, Jeong YH, Park Y, Yoon SE, Kwon TJ, Park JR, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S.

Br J Clin Pharmacol. 2012 Apr;73(4):629-40. doi: 10.1111/j.1365-2125.2011.04131.x.

PMID:
22007612
[PubMed - indexed for MEDLINE]
Free PMC Article
17.
18.

Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study.

Varenhorst C, Koul S, Erlinge D, Lagerqvist B, Siegbahn A, Wallentin L, James S.

Am Heart J. 2011 Aug;162(2):363-71. doi: 10.1016/j.ahj.2011.06.003. Epub 2011 Jul 20.

PMID:
21835299
[PubMed - indexed for MEDLINE]
19.

Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention.

Kim JY, Lee K, Shin M, Ahn M, Choe H, Yoo BS, Yoon J, Choe KH, Lee SH.

Circ J. 2007 Dec;71(12):1867-72. Erratum in: Circ J. 2008 Dec;72(12):2103.

PMID:
18037738
[PubMed - indexed for MEDLINE]
Free Article
20.

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, Suzuki Y, Box LC, Shoemaker SB, Zenni MM, Guzman LA, Bass TA.

Eur Heart J. 2008 Sep;29(18):2202-11. doi: 10.1093/eurheartj/ehn287. Epub 2008 Jun 21.

PMID:
18567918
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk